AnorMED licenses imaging technology to Bristol-Myers Squibb:
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb Medical Imaging has licensed technology for linking the imaging isotope technetium to a tissue-targeting agent from Vancouver, Canada-based AnorMED. BMS will use the HYNIC linker technology to develop diagnostic imaging products for cardiovascular diseases. AnorMED will receive an up-front payment of $0.1m and annual payments until 2007, as well as milestons and royalties. The same HYNIC technology has also been licensed to North American Scientific, which is developing a prognostic imaging agent for cancer and other diseases.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.